• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer
CardioCell

CardioCell

Breakthrough Cardiovascular Technology

  • About Us
    • Overview
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Our Stem Cells
    • Manufacturing
    • Quality Control
    • Exclusive License
  • Clinical Trials
    • Overview
    • Chronic Heart Failure
    • Heart Failure in Patients With Left Ventricular Assist Devices
    • Acute Myocardial Infarction
  • News
    • Press Releases
    • Media Coverage
    • Publications
  • Events
  • LinkedIn

News

September 7, 2016

Objective Capital Partners Adds CardioCell to Expanding Portfolio of Life Science Companies

News Sep 7, 2016 Objective Capital Partners Adds CardioCell to Expanding Portfolio of Life Science Companies SAN DIEGO – Sept. 7, 2016 – Objective Capital Partners, a leading middle market investment bank and mergers and acquisition (M&A) advisory firm focused on transactions for

Read More

News,  Press Releases

September 2, 2016

ESC: IV Stem Cells for Heart Failure: ‘A Lot More to Learn’

News Sep 2, 2016 ESC: IV Stem Cells for Heart Failure: 'A Lot More to Learn' Intravenous infusion of mesenchymal stem cells failed to improve cardiac function in heart failure patients but the treatment did appear to give patients some benefits such as improvement in physical

Read More

Media Coverage,  News

August 30, 2016

CardioCell reports Phase IIa heart failure data

News Aug 30, 2016 CardioCell reports Phase IIa heart failure data Data presented at the European Society of Cardiology meeting in Rome showed that a single intravenous administration of ischemic-tolerant mesenchymal stem cells (itMSCs) from CardioCell LLC met the primary safety

Read More

Media Coverage,  News

August 30, 2016

VIDEO – ESC 2016: beneficial effects of allogeneic mesenchymal stem cells in HF patients

News Aug 30, 2016 VIDEO - ESC 2016: beneficial effects of allogeneic mesenchymal stem cells in HF patients Javed Butler Describes the main findings from the Phase IIa CardioCell's Heart Failure study on the safety and efficacy of intravenous infusion of ischemia-tolerant allogeneic

Read More

Media Coverage,  News

August 30, 2016

IV Administration of Stem Cells Viable and More Practical Than Direct Cardiac Implantation

News Aug 30, 2016 IV Administration of Stem Cells Viable and More Practical Than Direct Cardiac Implantation MedicalResearch.com Interview with: Javed Butler, M.D., MPH, FACC, FAHA, Chief of the Cardiology Division and Co-Director of the Heart Institute at Stony Brook

Read More

Media Coverage,  News

August 30, 2016

CardioCell announces positive results from phase IIa study evaluating IV administration of stem cells for chronic HF indications

News Aug 30, 2016 CardioCell announces positive results from phase IIa study evaluating IV administration of stem cells for chronic HF indications CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announced data from its

Read More

Media Coverage,  News

August 29, 2016

CardioCell stem cells ‘improve well-being’ of heart failure patients

News Aug 29, 2016 CardioCell stem cells ‘improve well-being’ of heart failure patients After Celyad failed to reach its primary endpoints in a stem cell therapy test in heart patients back in June, CardioCell has felt the pressure to deliver--and over the weekend posted broadly

Read More

Media Coverage,  News

August 29, 2016

CardioCell offers bright spot in stem cell development

News Aug 29, 2016 CardioCell offers bright spot in stem cell development CardioCell reported positive Phase II data for its intravenous stem cell therapy for the treatment of chronic heart failure at the European Society of Cardiology meeting in Rome on Sunday. The study

Read More

Media Coverage,  News

  • « Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • …
  • Page 12
  • Next Page »

Primary Sidebar

Categories

  • Events
  • Media Coverage
  • News
  • Press Releases
  • Publications

Footer

About Us

  • Overview
  • Board of Directors
  • Scientific Advisory Board

Technology

  • Our Stem Cells
  • Manufacturing
  • Quality Control
  • Exclusive License

Clinical Trials

  • Overview
  • Chronic Heart Failure
  • Heart Failure in Patients With Left Ventricular Assist Devices
  • Acute Myocardial Infarction
<section id="bpfwp_contact_card_widget-1" class="widget widget_bpfwp_contact_card_widget"><div class="widget-wrap"><h3 class="widgettitle widget-title">Contact</h3>
info@stemcardiocell.com
</div></section>

Copyright © 2023 · Business Pro Theme on Genesis Framework · WordPress · Log in